Biorestorative Therapies (NASDAQ:BRTX) Trading 5.9% Higher – Still a Buy?

Shares of Biorestorative Therapies, Inc. (NASDAQ:BRTX) were up 5.9% during trading on Friday . The company traded as high as $0.2873 and last traded at $0.26. Approximately 45,434,601 shares were traded during trading, an increase of 4,766% from the average daily volume of 933,692 shares. The stock had previously closed at $0.2455.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Biorestorative Therapies currently has an average rating of “Sell”.

Biorestorative Therapies Stock Performance

The company has a fifty day moving average of $1.08 and a two-hundred day moving average of $1.33. The firm has a market capitalization of $2.31 million, a price-to-earnings ratio of -0.18 and a beta of 0.39.

Biorestorative Therapies (NASDAQ:BRTX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, meeting analysts’ consensus estimates of ($0.38). Biorestorative Therapies had a negative return on equity of 231.08% and a negative net margin of 3,308.09%.The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.46 million. Equities analysts forecast that Biorestorative Therapies, Inc. will post -1.43 EPS for the current year.

Institutional Trading of Biorestorative Therapies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC grew its position in shares of Biorestorative Therapies by 102.4% during the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after purchasing an additional 12,319 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Biorestorative Therapies in the third quarter valued at approximately $152,000. Finally, DRW Securities LLC bought a new stake in shares of Biorestorative Therapies in the fourth quarter valued at approximately $55,000. Institutional investors and hedge funds own 69.38% of the company’s stock.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.